Angiotensin Converting Enzymes (ACE) Inhibitors Market, by Drugs (Benazepril, Perindopril, Trandfolapril, Captopril, Enalapril, Lisinopril, Ramipril, and Others), by Application (Hypertension, Coronary Artery Disease, Heart Failure, Chronic Kidney Disease, Scleroderma, and Migraine), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

  • Published On : Jun 2019 |
  • Pages : 163 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Angiotensin Converting Enzymes (ACE) Inhibitors Market Insights

Angiotensin converting enzymes inhibitors are used to for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraines. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors are benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. ACE inhibitors are the first choice drugs for the treatment of hypertension. 

The global angiotensin converting enzymes (ACE) inhibitors market was valued at US$ 11,693.6 million in 2017, and is expected to witness a CAGR of 0.8% during the forecast period (2018 – 2026).

Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)

Angiotensin Converting Enzymes (ACE) Inhibitors  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of hypertension is expected to drive growth of the angiotensin converting enzymes (ACE) inhibitors market

Increasing prevalence of hypertension is one of the major drivers for the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, according to World Health Organization’s (WHO) report, in 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India.

Moreover, increasing number of research and development activities for improvement of cardiovascular functions during pregnancy is expected to propel the angiotensin converting enzyme (ACE) inhibitors market growth. For instance, in September 2018, Manchester University NHS Foundation Trust initiated clinical Phase II study of Enalapril Maleate for the pre-eclampsia condition. This study is for evaluating drug safety and efficacy on the patients. Pre-eclampsia condition is a pregnancy complication characterized by high blood pressure. It has various signs and symptoms including proteinuria, upper abdominal pain, and shortness of breath.

Angiotensin Converting Enzymes (ACE) Inhibitors Market - Regional Analysis

Regional segmentation of the global angiotensin converting enzymes (ACE) inhibitors market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share, owing increasing approval activities by the U.S. Food and Drug Administration (FDA). For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adult and in children.

Moreover, Europe is expected to gain significant share in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing product launch in this region. For instance, in September 2012, France-based Ceva Sante Animale S. A. launched its new combination drug, Benazepril and Spironolactone Tablet, for the treatment of heart failure in humans as well as in dogs.

Asia Pacific is also expected to witness significant growth in the angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing awareness activities regarding hypertension and its prevention in this region. For instance, in May 2018, Indian Council of Medical Research (ICMR) organized an awareness campaign on hypertension in collaboration with Public Health Foundation of India. According to ICMR, around 10.8% deaths annually caused by hypertension in India. Therefore, such programs will help to increase awareness for the treatment and management of hypertension, thereby supporting the ACE inhibitors market growth in this region.

Figure 2: Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value (US$ Mn), By Region, 2018

Angiotensin Converting Enzymes (ACE) Inhibitors  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Angiotensin Converting Enzymes (ACE) Inhibitors Market - Competitive Landscape

Key players operating in the angiotensin converting enzymes (ACE) inhibitors market include, Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and  Bayer AG.

Angiotensin converting enzymes (ACE) inhibitors act by inhibiting the angiotensin converting enzyme (ACE), which is an important component of renin angiotensin system. ACE inhibitors reduce the formation of angiotensin II and facilitate the dilation of blood vessels as well as reduce blood pressure. Angiotensin converting enzyme inhibitors also reduce blood pressure in kidneys. Angiotensin converting enzymes inhibitors (ACE) are effective for the treatment of congestive heart failure, stroke, and high blood pressure. However, overdose of ACE inhibitors may cause kidney failure, allergic reactions, angioedema, and neutropenia.

Market Dynamics

Increasing research and development activities related to study of ACE inhibitors is expected to boost the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, in February 2016, Monia Lorini, in collaboration with Istituto Di Ricerche Farmacologiche Mario Negri initiated clinical phase II study of ACE inhibitors (Lisinopril) for the treatment of extracapillary glomerulonephritis. This study is for evaluating drug safety and efficacy on the patients. It is expected to complete in December 2019.

Furthermore, in June 2014, Cardiology Research UBC initiated clinical trial phase IV to study the effects of statin including  Rosuvastatin and Ramipril - angiotensin converting enzymes inhibitors such as Ramipril on coronary flow reserve and microcirculatory resistance in patients with coronary artery dissection. This study is expected to complete in June 2021.

Overdose of angiotensin converting enzyme (ACE) inhibitors is a major factor restraining growth of the ACE inhibitors market. Overdose of ACE inhibitors may lead to various side effects such as dry cough, hyperkalemia (increased blood potassium level), dizziness, headache, and fatigue. Overdose of ACE inhibitors may also cause cancer. For instance, in October 2018, according to Medical Press (medical center in Melbourne, Australia), angiotensin converting enzymes (ACE) inhibitors are used for the treatment of high blood pressure. However, overdose of ACE inhibitors can increases the risk of lung cancer in patients. These drugs are responsible for the excessive production of bradykinin in the lungs. Excessive bradykinin is the main cause of lung cancer.

Key features of the study:

  • This report provides in-depth analysis of the angiotensin converting enzymes (ACE) inhibitors market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Pfizer, Inc., AstraZeneca, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company and Bayer AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for angiotensin converting enzymes (ACE) inhibitors market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs:
    • Benazepril
    • Perindopril
    • Trandolapril
    • Captopril
    • Enalaopril
    • Lisinopril
    • Ramipril
    • Others
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors  Market, By Application:
    • Hypertension
    • Coronary artery disease
    • Heart failure
    • Chronic kidney disease
    • Scleroderma
    • Migraine
  • Global  Angiotensin Converting Enzymes (ACE) Inhibitors  Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Angiotensin Converting Enzymes (ACE) Inhibitors market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drugs:
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney diseases
        • Scleroderma
        • Migraine
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drugs: 
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney disease
        • Scleroderma
        • Migraine       
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drugs:
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application:
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney disease
        • Scleroderma
        • Migraine
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drugs:
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney disease
        • Scleroderma
        • Migraine
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drugs:
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application:
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney disease
        • Scleroderma
        • Migraine
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drugs:
        • Benazepril
        • Perindopril
        • Trandolapril
        • Captopril
        • Enalaopril
        • Lisinopril
        • Ramipril
        • Others
      • By Application:
        • Hypertension
        • Coronary artery disease
        • Heart failure
        • Chronic kidney disease
        • Scleroderma
        • Migraine
      • By Distribution Channels:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca Pharmaceutical Company
    • Novartis AG
    • Daiichi Sankyo Company, Ltd.
    • United Therapeutics Corporation
    • Sanofi S.A.
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Takeda Pharmaceutical Company
    • Bayer AG

“*” marked represents similar segmentation in other categories in the respective section.

 

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drugs
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Pipeline Analysis
    • Epidemiology
    • Historical Overview
    • Merger and Acquisition
    • Regulatory Scenario
    • PEST Analysis
  4. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market, By Drugs, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Benazepril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Perindopril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Trandolapril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Captopril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Enalaopril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Lisinopril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Ramipril
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Application, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hypertension
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Coronary artery disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Heart failure
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Chronic kidney disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Scleroderma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Migraine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channels, 2016 – 2026, (US$ Million
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drugs, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca Pharmaceutical Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Daiichi Sankyo Company, Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • United Therapeutics Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Johnson & Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Analyst Views
  9. Section
  • References
  • Research Methodology
  • About us and Sales Contact

*Browse 29 market data tables and 25 figures on “Angiotensin Converting Enzymes (ACE) Inhibitors Market” - Global forecast to 2026”.

 

 

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.